secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theravance Biopharma, Inc. (TBPH)
CIK:        0001583107
Form:       8-K
Filed at:   2023-05-03T23:59:59+00:00
Accession:  0001104659-23-055518
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 3.03, 5.03, 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theravance shareholders approve 46% reduction in equity plan shares and board declassification
--------------------------------------------------------------------------------

- Shareholders approved amendment to 2013 Equity Incentive Plan: extended term 10 years, eliminated evergreen, reduced shares reserved by 3,808,287 (46% reduction).
- Shareholders approved amendment to declassify Board of Directors over time.
- Director nominees elected: Dean J. Mitchell and Deepika R. Pakianathan elected Class III directors.
- Ernst & Young ratified as independent auditor for fiscal year ending Dec 31, 2023.
- Non-binding advisory vote on executive compensation approved; shareholders voted for annual frequency.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583107/000110465923055518/0001104659-23-055518-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583107/000110465923055518/tm2314493d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-055518

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer